After birth · Ranked on oversight · Updated October 2026
The months after a birth are the ones where a GLP-1 is most often asked about and least often studied. This board ranks only providers that can prescribe the FDA-approved medication — the version with pregnancy and lactation labeling your OB can actually read — and that put a clinician rather than a form in front of the prescription.
The short answer
Start with the timing, not the vendor. There is no approved postpartum start date, GLP-1s are not for use in pregnancy or while trying to conceive, and the breastfeeding evidence is thin rather than reassuring — our reporting on what the postpartum data actually says lays out where the gaps are. Any provider offering you certainty on that is selling.
Of the 353 providers we score, 35 both offer FDA-approved medication and clear our clinical-oversight bar. Sesame is listed first, at 80/100 — providers we work with may appear first, and scores are our own. Price is deliberately not the ranking factor here — if it is your binding constraint, the cash-pay board is the honest place to start instead.
CoreAge Rx is a featured partner, and providers we work with may appear first. Scores are our own — the Editors’ Rating is printed on every row so you can check it.
A high-trust telehealth marketplace that took a clear side: FDA-approved brand GLP-1 only, no compounded shortcut. You pay a brand cash price and book a real video visit — but you get on-label pens and one of the cleaner reputations on this masthead.
The rare program that will write you either a compounded vial or an FDA-approved pen and bill the visit through your insurance, holding one price at every dose. The catch is the calendar: the cheap headline needs a year paid upfront, and every refill needs a video call.
One price at every dose: $249 for semaglutide or $299 for tirzepatide month to month, falling to $199 on three months and $129 or $179 on a prepaid year — a reasonable all-doses-included option, if you can live with a pharmacy the marketing never names.
RxSpan MD is a genuinely well-disclosed service wrapped in marketing that undercuts it. The disclosure: four compounding pharmacies named with phone numbers, two lead physicians named with NPI numbers that verify as active MDs, flat pricing posted before any intake, both compounded and real FDA-approved brand GLP-1s on one platform, and oral capsules for anyone who won't inject. Compounded semaglutide is $249 a month and tirzepatide $329, with brand Zepbound at $1,069, Ozempic at $1,299 and Wegovy at $1,349. The marketing is the problem. Its testimonials still name a different company — one patient describes what she 'expected from CareGLP' — and the doctors quoted in them are not the clinicians the same page names as its medical team. The homepage is built around a board-certified plastic surgeon who founded the practice but is licensed in California only and isn't the prescriber. Its compounded prices also sit above the median price on our list, and the oral capsules cost the same or more than the injections.
A women's-condition clinic that happens to prescribe GLP-1s, rather than a weight-loss program wearing a women's-health skin — an OBGYN and a dietitian on every case, real labs, and an every-other-week check-in for a flat $149 with no commitment. The drug is not in that number, and Allara writes brand pens only.
The closest thing on this masthead to an actual obesity-medicine clinic online — a board-certified physician and a registered dietitian on your case, monthly video visits, and a real effort to run treatment through your insurance. The $299 self-pay fee is for that care team, not the medication.
The only program on this masthead that bills insurance, which changes the arithmetic more than any discount here. The visit is covered in network or costs $250 self-pay, and the medication is billed separately from $165.90 per four-week supply for injectable semaglutide and $210 for tirzepatide — both the visit fee and a full dose table published, which is what makes the model reviewable at all.
A cardiometabolic telehealth platform — diabetes and weight management together — with a $149/mo membership (or no fee if your insurance covers it) for specialist visits, labs, devices and coaching. It prescribes only FDA-approved brand GLP-1s (Wegovy, Zepbound, Saxenda), and what that medication costs you depends on your insurance; no out-of-pocket price is published. There is no state list, and its own branding leans more toward diabetes than weight loss.
The best-funded option on the board: real brand-name Wegovy and Zepbound access, a dedicated insurance concierge, and an app that rarely breaks — with the catch that the membership fee and the medication cost are always two separate charges, and it doesn't say whether check-ins are video or async.
A year-long metabolic program that treats the medication as one lever and intensive human coaching as the other — a disclosed $199/mo membership with a 3-month minimum, a real 20-minute video visit, and insurance doing most of the work on the medication itself.
PlushCare is an online primary-care practice rather than a weight-loss storefront: a physician orders labs, prescribes brand-name GLP-1s such as Wegovy or Zepbound if you qualify, sends the prescription to your own pharmacy and handles the insurance prior authorization. The visit is your copay — under $30 for most insured patients — or $129 without insurance, and a $19.99 monthly membership covers you and up to five family members. What it cannot tell you is the price of the medication, because your pharmacy and insurer set it.
Every other seller on this page quotes a month. This one quotes a week, and the difference is enormous: $115 a week is about $500 a month, three or four times the telehealth rate. It is also a different thing entirely. That price is all-inclusive and buys a weekly in-person appointment with a provider, vitals and a weigh-in, fifty-two times a year, at one of fifteen clinics in Maryland and Virginia. Its telehealth plan is priced by the month instead: $399 for semaglutide and $599 for tirzepatide, with a monthly video visit.
A nationwide, physician-led program that has shifted from compounded to brand-name medication now that the FDA shortage exemption has ended — a disclosed $149/mo membership plus a separately billed drug cost, honest about the shift even where the number is bigger than it used to look.
Pallas Health is a rare thing in this category: a platform that sells both the inexpensive compounded route and the genuine FDA-approved pens, and is straightforward about the price of each. Compounded semaglutide is $199 every four weeks and tirzepatide $299, while brand Zepbound is $1,069, Ozempic $1,299, and Wegovy and Mounjaro $1,349 each, all cash-pay, and the Foundayo tablet is $499 every four weeks. Its own FAQ answers the question that matters most on a titration schedule — does the price rise with the dose — with a flat no, and the clinician, dose adjustments, check-ins and messaging are all inside the plan price with no membership fee. Two named clinicians are active in the federal NPI registry, the LegitScript seal links back to LegitScript's own records, and no FDA warning letter is attributable to the company. The reservations are specific rather than sweeping — plans renew every four weeks, so a year holds 13 charges, the compounding pharmacy is never named, and insurance is not billed at all.
The one program on this masthead that treats menopause and the postpartum year as clinical facts rather than marketing, wrapped around brand-name pens and an insurance coordinator who makes the calls. Then it sells you a year you cannot leave.
Maven Clinic built its name on maternity, fertility and menopause care sold through employers, and its new self-pay GLP-1 program brings that women's-health depth to weight care. You pay a $150 monthly membership ($39 the first month) for unlimited clinician support, a nutrition coach and a strength coach, plus FDA-approved medication billed by the pharmacy — about $299 a month all-in for the Wegovy pill and $449 for starting-dose Zepbound. Every dose has a published price, which is rare, but the two-charge structure makes it one of the pricier ways to start.
FDA warning letters dated 9 September 2025, over the compounded-semaglutide business it has since left behind. Through the Hers front door, a mass-market brand now selling FDA-approved brand-name GLP-1s — Wegovy, Zepbound, Ozempic — instead of the compounded semaglutide it used to. The posted price is only half the bill: a required $149/mo membership sits on top of whatever the medication costs, so the real monthly number is roughly double what the landing page shows.
Midlife-focused weight care with physician messaging and both compounded and FDA-approved brand options. Add the required $99 monthly care fee: compounded semaglutide starts at $169 all-in and tirzepatide at $199. These are starting figures, not a published maintenance-dose ladder. Compounds are unavailable in six states and DC.
The rare compounded program that names its doctors and puts a real 30-minute video visit in front of the prescription — and then prices itself in two pieces, so the $60 on the front page is well under half what leaves your account once the $79 clinic fee is added.
One of the only programs on our list offering both molecules as an injection AND a needle-free oral tablet, in all 50 states — but its $179/mo semaglutide headline is a stated summer promo, not a locked-in rate, and its "15-22% weight loss" claim is self-reported customer data, not a clinical trial.
A concierge functional-medicine platform that bundles a 91-biomarker lab panel into GLP-1 care — $199/mo semaglutide, $399/mo tirzepatide month to month, less on three- or six-month commitments — rather than selling the medication as a bare subscription.
Starts at $189/mo for semaglutide or $199/mo for tirzepatide, $40 less on your first order, and scales up with your dose to $299–$389/mo at the top tier. A $199 oral tablet and brand-name Wegovy and Zepbound are also available, in 48 states (all but AL and MS), with a cancel-or-pause-anytime policy.
The women's-health platform a lot of mothers already have an account with, extended to weight management — and priced as care rather than medication. The $79-plus-$79 is honest and modest; the four-figure retail pen it does not include is not.
A nurse-practitioner-led, brand-only clinic — Wegovy or Zepbound "from Eli Lilly or Novo Nordisk," never compounded — with a $75/mo membership or a $99 pay-as-you-go alternative and HSA/FSA accepted, though the medication cost itself is billed separately and varies by pharmacy, and coverage is a small seven-state footprint in the South and Southwest.
A major, highly recognizable brand — Amazon's own One Medical plus Amazon Pharmacy channel — offering FDA-approved brand GLP-1s at coupon prices: the Wegovy pill from $149 a month, the Wegovy pen from $199 and the Zepbound KwikPen from $299 per 28 days, plus the oral Foundayo pill. Every one of those depends on coupon eligibility, and the care visit is billed separately, from $39.
| # | Provider | From | States | Rating |
|---|---|---|---|---|
| 1 | Sesame | See review | All 50 states | 80 · B− |
| 2 | Found | $289/4 wk | See review | 76 · C |
| 3 | Gala Health | $249/4 wk | All 50 states | 82 · B− |
| 4 | RxSpan MD | $249/mo | All 50 states | 69 · C |
| 5 | Allara Health | See review | 45 states | 83 · B |
| 6 | Form Health | See review | See review | 81 · B− |
| 7 | Midi Health | $165.9/4 wk | All 50 states | 80 · B− |
| 8 | 9amHealth | See review | See review | 66 · C |
| 9 | Ro | See review | All 50 states | 80 · B− |
| 10 | Calibrate | See review | See review | 79 · C |
| 11 | PlushCare | See review | All 50 states | 66 · C |
| 12 | Rivas Medical Weight Loss | $399/mo | See review | 55 · C |
| 13 | LifeMD | See review | All 50 states | 80 · B− |
| 14 | Pallas Health | $199/4 wk | All 50 states | 78 · C |
| 15 | WeightWatchers Clinic | See review | See review | 78 · C |
| 16 | Maven Clinic | See review | See review | 74 · C |
| 17 | Hims & Hers | See review | All 50 states | 76 · C |
| 18 | Alloy | $169/mo | See review | 73 · C |
| 19 | Mochi Health | $139/mo | All 50 states | 77 · C |
| 20 | OnlyRx | $179/mo | All 50 states | 70 · C |
| 21 | Heva Health | $199/mo | 46 states | 61 · C |
| 22 | WePeptideRx | $189/mo | 48 states | 78 · C |
| 23 | Nurx | See review | See review | 70 · C |
| 24 | The Virtual NP | See review | See review | 69 · C |
| 25 | Amazon One Medical | See review | See review | 57 · C |
There is no approved postpartum start date, and any provider who gives you a confident number is going beyond the evidence. What is settled: GLP-1s are not for use in pregnancy or while trying to conceive, and the drug should be cleared from your system well before a next pregnancy — tirzepatide additionally carries a contraception instruction semaglutide does not. What is not settled is breastfeeding, where the human data is thin rather than reassuring. This is a conversation for a clinician who knows your delivery, your feeding plans and your history, which is why this board ranks on clinical oversight rather than on price.
The honest answer is that nobody can tell you with confidence. The manufacturers advise against it, the human data is limited, and what exists studies the FDA-approved products rather than compounded versions — which is one reason this board is restricted to providers that can prescribe brand-name medication with its own lactation labeling. A compounded vial has no such document. Decide it with a clinician, not with a board, and treat anyone selling certainty here as selling.
Because the labeling is the point. Wegovy, Zepbound, Ozempic and Mounjaro carry the manufacturer's own pregnancy and lactation sections — a document your OB can read. Compounded semaglutide, whatever its price advantage elsewhere on this masthead, has no equivalent. Of the 353 providers we score, 35 both offer FDA-approved medication and clear our clinical-oversight bar, and those are the ones ranked here.
It is not established either way, and that uncertainty is itself worth knowing. The mechanism gives reason for caution — these drugs work partly by reducing intake, and lactation has real caloric demands — but that is a mechanism argument, not a finding, and we label it as such rather than dressing it up. If you are nursing and considering starting, supply is a question to raise explicitly, because a provider who has not thought about it will not raise it for you.
Four things, and the answers tell you most of what you need: how long after delivery they will prescribe and why that interval; whether they prescribe the FDA-approved product or a compounded version, and what labeling exists for it; whether you will speak to a clinician who reads your delivery history, or complete an async form; and what happens to the price and the plan if you stop. A provider that answers all four plainly is the kind this board is built to find.
Read what to tell your OB before starting and the one breastfeeding study two sides both claim. If insulin resistance or the midlife shift is the driver rather than a recent birth, the PCOS and menopause board is scored for that instead. Nothing here is medical advice, and no board can replace a clinician who knows your delivery and your feeding plans.
Keep exploring
Each board answers a different mother's situation. CoreAge Rx is a featured partner, and providers we work with may appear first.